TAIPEI, Taiwan, Aug. 6, 2012 /PRNewswire-Asia/ -- TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications. In the intent-to-treat population, AC-201 showed placebo-corrected reductions in HbA1c of 0.20%, 0.29%, and 0.35%*(* indicates statistical significance with p<0.05) after 24 weeks of treatment in the three tested dose groups of 25 mg, 50 mg, and 75mg twice daily (b.i.d), respectively. In the per-protocol population, the placebo-corrected reduction in HbA1c was 0.37%, 0.42%*, and 0.49%*, for 25 mg, 50 mg, and 75 mg b.i.d dose groups, respectively. AC-201 showed good dose response and was well tolerated up to 75 mg b.i.d. The most frequent side effect was diarrhea that was mostly mild.
The clinical trial was conducted in the United States, where 150 patients were enrolled in 13 sites, and Taiwan, where 109 patients were enrolled in 8 sites. Further analysis revealed that AC-201 in the US cohort demonstrated placebo-corrected HbA1c reductions in the per-protocol population of 0.61%*, 0.72%*, and 0.93%*, for 25 mg, 50 mg, and 75mg b.i.d dose groups, respectively. The differences in patient profiles such as BMI (mean baseline of 27 kg/m square in Taiwan vs. 32kg/m square in the US), background anti-diabetic therapy (54% in Taiwan vs. 9% in the US of patients taking 3 oral anti-diabetic drugs), and medical practices between the two cohorts are possible reasons for the differences in efficacy results.
“We are pleased to see AC-201 once again demonstrated a good potential to be a treatment for patients with type II diabetes; the data from patients in the US are especially encouraging,” said Calvin Chih-Kuang Chen, Ph.D., acting president of TWi Pharmaceuticals. Referencing AC-201’s unique mode of action that targets the inflammation pathway associated with both impaired beta-cell function and insulin resistance, Dr. Dee Pei, Professor of Medicine, Fu Jen Catholic University and Chief of Internal Medicine, Cardinal Tien Hospital, Taipei, Taiwan, said: “I am mostly impressed by AC-201’s ability to reduce HbA1c levels in those very difficult to treat patients. AC-201 could be a very useful tool when combinations of drugs are required to achieve successful control of blood sugar in certain type II diabetic patients.”
About AC-201
AC-201 is the only orally available small molecule in development which modulates the intracellular synthesis of the cytokine IL-1Beta. Inhibition of IL-1Beta signaling has been demonstrated to be effective in treating a variety of inflammatory diseases including arthritis, diabetic nephropathy (DN) and diabetic mellitus (DM).
About TWi Biotechnology
TWi Biotechnology, Inc. (www.twipharma.com), a fully owned subsidiary of TWi Pharmaceuticals, Inc., is a leading biopharmaceutical company based in Taipei, Taiwan. The company specializes in in-licensing and developing innovative new drugs for unmet medical needs. With solid experience in regulatory affairs and clinical development, the company can expedite the development process of drug candidates for the worldwide market. The company is building its product pipeline through in-licensing of late pre-clinical stage drug candidates from renowned pharmaceutical companies and research/academic institutions. The company is in active development of four therapeutic candidates to treat Type II Diabetes complications, retinopathy, cancer, and dermatology diseases.
SOURCE TWi Pharmaceuticals, Inc.
